Literature DB >> 6548711

Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.

R Bergstrand, A Vedin, C Wilhelmsson, L E Peterson, J Chamberlain, D Dell, L A Stevens, J Ostrowski.   

Abstract

In 12 healthy male volunteers, molsidomine 1, 2 and 4 mg i.v. increased resting heart rate and decreased systolic blood pressure, the latter still being affected after 8 hours. After single oral doses of 1 and 2 mg, systolic pressure tended to be reduced for 90 minutes and exercise heart rate tended to be increased. After oral treatment with 2 mg molsidomine three times daily for 1 week, the pharmacokinetic parameters and the effects on heart rate and blood pressure after the final dose were not different from those after the first dose. The terminal half-life was independent of dose and route of administration. Clearance and distribution volume were not dose-dependent. The bioavailability of a 2 mg oral dose of molsidomine was 44%. Inter-individual variation in heart rate, blood pressure and pharmacokinetics was observed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6548711     DOI: 10.1007/bf00544046

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  [Molsidomin in coronary disease. Clinico-pharmacokinetic correlation study on the effect of oral and sublingual therapy].

Authors:  R Strasser; H Klepzig; J Ostrowski; K Resag
Journal:  MMW Munch Med Wochenschr       Date:  1983-02-25

2.  Haemodynamic effects of molsidomin.

Authors:  K R Karsch; K P Rentrop; H Blanke; H Kreuzer
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

3.  Acute double blind trial of a new anti-anginal drug: molsidomine.

Authors:  S Guerchicoff; A Vazquez; H Kunik; S Drajer; F Díaz
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

4.  Molsidomine in the treatment of patients with angina pectoris.

Authors:  P A Majid; P J DeFeyter; E E Van der Wall; R Wardeh; J P Roos
Journal:  N Engl J Med       Date:  1980-01-03       Impact factor: 91.245

5.  Determination of molsidomine in plasma by high-performance liquid column chromatography.

Authors:  D Dell; J Chamberlain
Journal:  J Chromatogr       Date:  1978-11-01

6.  Comparative study of the haemodynamic effects of oral molsidomine and isosorbide dinitrate in man.

Authors:  A Vogt; H Kreuzer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Double-blind controlled trial of molsidomine in hypertension.

Authors:  J Milei; A Vazquez; J Lemus
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

8.  Hemodynamic effects of molsidomine vasodilatory therapy in acute myocardial infarction.

Authors:  M Aptecar; C A Otero y Garzon; A Vasquez; S Varini; L Collia; A Esteguy; S Caruso
Journal:  Am Heart J       Date:  1981-04       Impact factor: 4.749

9.  [Molsidomine in ergometric tests (author's transl)].

Authors:  D Röhl; K H Lehmann
Journal:  Dtsch Med Wochenschr       Date:  1980-08-29       Impact factor: 0.628

  9 in total
  4 in total

1.  Pharmacokinetic profile of a novel slow release preparation of molsidomine.

Authors:  S Rietbrock; B Keller-Stanislawski; P Thürmann; D Brockmeier
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Clinical pharmacokinetics of molsidomine.

Authors:  B Rosenkranz; B R Winkelmann; M J Parnham
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.